Clinical trials: Low Risk Prostate Cancer
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce…
- Trial name
- NCT03436654
- Testing
- Apalutamide, Abiraterone Acetate, Prednisone
- Where
- 11 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon